

Supplementary Table 7. Trends in dual combination antidiabetic agents among insulin users with type 2 diabetes mellitus from 2011 to 2019

	2011	2012	2013	2014	2015	2016	2017	2018	2019
Metformin+SU	40,068 (15.79)	45,893 (17.8)	48,167 (18.61)	49,797 (19.18)	32,144 (12.09)	26,761 (9.32)	25,461 (8.23)	24,447 (7.36)	23,103 (6.63)
Metformin+DPP-4i	3,182 (1.25)	3,562 (1.38)	4,149 (1.6)	4,172 (1.61)	43,201 (16.25)	62,846 (21.89)	74,494 (24.08)	84,032 (25.29)	90,802 (26.07)
Metformin+SGLT2i	-	-	-	106 (0.04)	3,044 (1.15)	8,425 (2.93)	13,447 (4.35)	17,509 (5.27)	23,915 (6.87)
Metformin+GLP-1 RA	6 (<0.01)	5 (<0.01)	7 (<0.01)	1 (<0.01)	195 (0.07)	804 (0.28)	2,032 (0.66)	4,562 (1.37)	6,227 (1.79)
Metformin+TZD	725 (0.29)	791 (0.31)	1,289 (0.5)	1,656 (0.64)	3,351 (1.26)	3,739 (1.30)	4,185 (1.35)	4,560 (1.37)	4,715 (1.35)
Metformin+Meglitinide	1,764 (0.70)	1,382 (0.54)	1,157 (0.45)	964 (0.37)	1,476 (0.56)	1,391 (0.48)	1,263 (0.41)	1,125 (0.34)	1,012 (0.29)
Metformin+AGI	4,394 (1.73)	2,587 (1.00)	1,681 (0.65)	1,500 (0.58)	1,786 (0.67)	1,666 (0.58)	1,769 (0.57)	1,606 (0.48)	1,413 (0.41)
SU+DPP-4i	178 (0.07)	563 (0.22)	815 (0.31)	1,040 (0.40)	9,039 (3.40)	13,513 (4.71)	16,789 (5.43)	19,108 (5.75)	20,471 (5.88)
SU+SGLT2i	-	-	-	23 (0.01)	327 (0.12)	763 (0.27)	1,037 (0.34)	1,148 (0.35)	1,320 (0.38)
SU+GLP-1 RA	1 (<0.01)	1 (<0.01)	1 (<0.01)	-	8 (<0.01)	16 (0.01)	54 (0.02)	131 (0.04)	155 (0.04)
SU+TZD	740 (0.29)	467 (0.18)	455 (0.18)	514 (0.20)	792 (0.30)	1,004 (0.35)	1,109 (0.36)	1,199 (0.36)	1,136 (0.33)
SU+AGI	2,398 (0.94)	1,331 (0.52)	895 (0.35)	627 (0.24)	650 (0.24)	581 (0.20)	532 (0.17)	484 (0.15)	409 (0.12)
TZD+DPP-4i	5 (<0.01)	18 (0.01)	44 (0.02)	90 (0.03)	2,861 (1.08)	4,682 (1.63)	5,789 (1.87)	6,336 (1.91)	6,592 (1.89)
Meglitinide+AGI	398 (0.16)	183 (0.07)	177 (0.07)	138 (0.05)	457 (0.17)	476 (0.17)	523 (0.17)	532 (0.16)	461 (0.13)

Values are presented as number (%).

SU, sulfonylurea; DPP-4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium glucose cotransporter 2 inhibitor; GLP-1 RA, glucagon-like peptide-1 receptor agonist; TZD, thiazolidine-dione; AGI, alpha glucosidase inhibitor.